文献速递浆细胞疾病

抑制骨细胞特异性蛋白硬化蛋白可增加多发性骨髓瘤的骨量和抗骨折能力

Inhibiting the osteocyte-specific protein sclerostin increases bone mass and fracture resistance in multiple myeloma.
PubMed 文献 · Blood · 2017-05-17

多发性骨髓瘤(MM)骨病由破骨细胞骨吸收增加和骨形成受抑所致,双膦酸盐不能促进骨形成或修复已丢失的骨。本研究在MM小鼠模型中证实,抗硬化蛋白抗体可增加成骨细胞数量和骨形成率,不抑制骨吸收或减少肿瘤负荷,但能预防骨髓瘤诱导的骨丢失、减少溶骨性病变并增加抗骨折能力;与唑来膦酸单药相比,联合治疗进一步增加骨量和抗骨折能力。

要点

  • 硬化蛋白在幼稚和荷瘤小鼠骨的骨细胞中表达,但在630例骨髓瘤患者浆细胞和54个骨髓瘤细胞系中不表达。
  • 抗硬化蛋白抗体增加成骨细胞数量和骨形成率,但不抑制骨吸收或减少肿瘤负荷。
  • 抗硬化蛋白抗体与唑来膦酸联合较唑来膦酸单药增加骨量和抗骨折能力。

核心结论

  • 抑制硬化蛋白可预防骨髓瘤诱导的骨丢失、减少溶骨性病变并增加抗骨折能力。
  • 抗硬化蛋白抗体与唑来膦酸联合较唑来膦酸单药增加骨量和抗骨折能力,作者认为该策略优于当前标准治疗并减少MM患者骨折。

研究设计与样本

  • 研究在幼稚和荷瘤小鼠中检测硬化蛋白表达,并在630例骨髓瘤患者浆细胞和54个骨髓瘤细胞系中检测硬化蛋白表达。
  • 小鼠注射5TGM1-eGFP、5T2MM或MM1.S骨髓瘤细胞后出现显著骨丢失,并与椎骨抗骨折能力下降相关。

主要发现

  • 硬化蛋白在幼稚和荷瘤小鼠骨的骨细胞中表达,但在630例骨髓瘤患者浆细胞和54个骨髓瘤细胞系中不表达。
  • 注射5TGM1-eGFP、5T2MM或MM1.S骨髓瘤细胞的小鼠出现显著骨丢失,并与椎骨抗骨折能力下降相关。
  • 抗硬化蛋白抗体治疗增加成骨细胞数量和骨形成率,但不抑制骨吸收或减少肿瘤负荷。
  • 抗硬化蛋白抗体治疗预防骨髓瘤诱导的骨丢失、减少溶骨性病变并增加抗骨折能力。
  • 抗硬化蛋白抗体与唑来膦酸联合较唑来膦酸单药增加骨量和抗骨折能力。

临床怎么用

  • 作者认为该研究定义了一种优于当前标准治疗的治疗策略,将减少MM患者骨折。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Multiple myeloma (MM) is a plasma cell cancer that develops in the skeleton causing profound bone destruction and fractures. The bone disease is mediated by increased osteoclastic bone resorption and suppressed bone formation. Bisphosphonates used for treatment inhibit bone resorption and prevent bone loss but fail to influence bone formation and do not replace lost bone, so patients continue to fracture. Stimulating bone formation to increase bone mass and fracture resistance is a priority; however, targeting tumor-derived modulators of bone formation has had limited success. Sclerostin is an osteocyte-specific Wnt antagonist that inhibits bone formation. We hypothesized that inhibiting sclerostin would prevent development of bone disease and increase resistance to fracture in MM. Sclerostin was expressed in osteocytes from bones from naive and myeloma-bearing mice. In contrast, sclerostin was not expressed by plasma cells from 630 patients with myeloma or 54 myeloma cell lines. Mice injected with 5TGM1-eGFP, 5T2MM, or MM1.S myeloma cells demonstrated significant bone loss, which was associated with a decrease in fracture resistance in the vertebrae. Treatment with anti-sclerostin antibody increased osteoblast numbers and bone formation rate but did not inhibit bone resorption or reduce tumor burden. Treatment with anti-sclerostin antibody prevented myeloma-induced bone loss, reduced osteolytic bone lesions, and increased fracture resistance. Treatment with anti-sclerostin antibody and zoledronic acid combined increased bone mass and fracture resistance when compared with treatment with zoledronic acid alone. This study defines a therapeutic strategy superior to the current standard of care that will reduce fractures for patients with MM.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. McDonald MM, Reagan MR, Youlten SE, et al. Inhibiting the osteocyte-specific protein sclerostin increases bone mass and fracture resistance in multiple myeloma. Blood. 2017. PMID: 28515094. doi:10.1182/blood-2017-03-773341

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。